139 Results for "

GPCRs

" in MedChemExpress (MCE) Product Catalog:
Products (139)

139 Results for "GPCRs" in MCE Product Catalog:

Cat. No.: HY-L099
2,294 compounds

MCE Targeted Diversity Library contains 2,294 compounds, covering more than 1000 targets and isoforms, such as GPCRs, Ion channel, variety of kinases, etc. 1-3 compounds with high potency and selectivity were carefully selected for each target and isoform. The bioactivity information of each compound has been clearly reported in the literatures. This library is a concise collection of small molecule compounds with comprehensive target coverage, which can be used for phenotypic screening at low cost.

Cat. No.: HY-P991761

Target:  

CXCR

Research Areas:  

Inflammation/Immunology

Anti-Mouse CXCL10 Antibody (1F11) is a mouse CXCL10 antibody. Anti-Mouse CXCL10 Antibody (1F11) blocks the activity of CXCL10 and inhibits GPCR-dependent interstitial motility of Th1 cells in inflamed dermis. Anti-Mouse CXCL10 Antibody (1F11) can be used for research on inflammation-related diseases. Recommended isotype control: Polyclonal Armenian hamster IgG, Isotype Control (HY-P990305) .
loading...
    loading...
Cat. No.: HY-101008
CAS No.: 133399-65-2
3-MPPI is a GPCR ligand with high selectivity for α1-adrenergic receptor, with a Ki value of 0.21 nM for α1-adrenergic receptor and 50 nM for 5-HT1A receptor. 3-MPPI modulates the α1-adrenergic receptor signaling cascade. 3-MPPI is applicable to research related to hypertension, stress-induced anxiety-like behavioral responses, and levodopa-induced dyskinesia .
loading...
    loading...
Cat. No.: HY-187642
CAS No.: 303059-39-4
Research Areas:  

Cancer

IGGi-11 is a competitive Gαi inhibitor with a Kd of 5.3 μM for sGαi3. IGGi-11 binds to the GIV interaction region of Gαi3, blocks non-canonical G protein signaling, and does not interfere with Gαi nucleotide processing, Gβγ binding, GPCR activation, or effector regulation. IGGi-11 inhibits the pro-invasive properties of metastatic breast cancer. IGGi-11 can be used in related studies on metastatic breast cancer .
loading...
    loading...
Cat. No.: HY-107625AR
CAS No.: 1781934-47-1
Research Areas:  

Neurological Disease

SNAP 94847 hydrochloride (Standard) is the analytical standard of SNAP 94847 (hydrochloride) (HY-107625A). This product is intended for research and analytical applications. SNAP 94847 hydrochloride is a novel, high affinity selective melanin-concentrating hormonereceptor1 (MCHR1) antagonist with (Ki= 2.2 nM, Kd=530 pM), it displays >80-fold and >500-fold selectivity over MCHα1A and MCHD2 receptors respectively. SNAP 94847 hydrochloride binds with high affinity to the mouse and rat MCHR1 with minimal cross-reactivity to other GPCR, ion channels, enzymes, and transporters .
loading...
    loading...
Cat. No.: HY-115702
CAS No.: 77286-68-1
Synonyms: (Rac)-PAF (C16)
1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine ((Rac)-PAF (C16)) is an endogenous inflammatory lipid mediator. 1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine acts as a high-affinity agonist for PAFR (GPCR), inducing platelet aggregation, vascular permeability, and leukocyte chemotaxis at extremely low concentrations. 1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine exerts its effects via cell surface receptors to regulate inflammation .
loading...
    loading...
Cat. No.: HY-181287
Research Areas:  

Inflammation/Immunology

PROTAC CCR9 Degrader 1 is a PROTAC-based degrader targeting CCR9. PROTAC CCR9 Degrader 1 induces ubiquitination, proteasomal degradation of CCR9 and reduces intracellular CCR9 levels by recruiting the VHL E3 ligase. PROTAC CCR9 Degrader 1 has a Ki value of 78.0 nM against human CCR9. PROTAC CCR9 Degrader 1 modulates GPCR activity by binding to the intracellular allosteric binding site of CCR9. PROTAC CCR9 Degrader 1 can be used in research related to Crohn's disease .
loading...
    loading...
Cat. No.: HY-L159
2,192 compounds

Agonistic drugs activate or stimulate their receptors, triggering responses that increase or decrease cell activity. The highly selective activators can act on specific biological or molecular targets, while non-selective activators may interfere with multiple targets or targets simultaneously. The highly selective activators reduce the likelihood of these non-specific effects by targeting specific targets, making research more precise and reliable. The Highly Selective Activators Library contains 2,192 compounds, covering multiple targets and subtypes, such as GPCR protein family, Ion channel, multiple kinases, etc. The Highly Selective Activators Library is an effective tool for screening different phenotypes.

Cat. No.: HY-103080R
CAS No.: 1586787-08-7
CMF019 (Standard) is the analytical standard of CMF019 (HY-103080). This product is intended for research and analytical applications. CMF019 is an orally active, potent and small molecule agonist at Apelin receptor (APJ) with G protein bias. CMF019 binds to APJ with pKi values of 8.58, 8.49 and 8.71 for human, rat, and mouse, respectively. CMF019 mimics the beneficial cardiovascular actions of apelin in rodents . Apelin receptor (APJ) is a G protein-coupled receptor (GPCR) activated by the endogenous peptide apelin. CMF019 is promising for research of chronic diseases, such as, pulmonary arterial hypertension .
loading...
    loading...
Cat. No.: HY-129636
CAS No.: 1611483-29-4
Synonyms: (E)-GABAB receptor antagonist 1
Target:  

GABA Receptor ERK

Research Areas:  

Neurological Disease

CLH304a (compound 14) is a specific and noncompetitive GABAB receptor negative allosteric modulator (NAM). CLH304a decreases GABA-induced IP3 production with an IC50 of 37.9 μM. CLH304a has no effect on other GPCR Class C members such as mGluR1, mGluR2, and mGluR5. CLH304a acts on the heptahelical domain of GB2 subunits and non-competitively inhibits the effect of agonists with inverse agonist properties. CLH304a inhibits Baclofen (HY-B0007)-induced ERK1/2 phosphorylation in HEK293 cells overexpressing GABAB receptor .
loading...
    loading...
Cat. No.: HY-15589R
CAS No.: 885101-89-3
GW9508 (Standard) is the analytical standard of GW9508. This product is intended for research and analytical applications. GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .
loading...
    loading...
Cat. No.: HY-184442
Target:  

G2A (GPR132)

Research Areas:  

Neurological Disease

GPR132 antagonist-2 is a G2A (GPR132) antagonist with an IC50 of 0.69 μM. GPR132 antagonist-2 exerts weak stabilizing effects on the bromodomain of BRD2 and exhibits selectivity for non-olfactory GPCRs. GPR132 antagonist-2 inhibits G2A activation, blocks downstream inositol monophosphate accumulation, reverses G2A-mediated TRPV1 sensitization, suppresses 9-HODE-mediated capsaicin-induced TRPV1 responses, and activates FPR3. GPR132 antagonist-2 can be used in studies related to neuropathic pain .
loading...
    loading...
Cat. No.: HY-W010448R
CAS No.: 22884-10-2
Imidazol-1-yl-acetic acid (Standard) is the analytical standard of Imidazol-1-yl-acetic acid (HY-W010448). This product is intended for research and analytical applications. Imidazol-1-yl-acetic acid is a BRS-3 agonist that mediates anorectic effects through activation of orphan G protein-coupled receptors (Orphan GPCR) in peripheral tissues; it also serves as a green, water-soluble, recyclable bifunctional organocatalyst for transformations such as the Biginelli multicomponent reaction and epoxide ring opening. Imidazol-1-yl-acetic acid can be used for research on obesity .
loading...
    loading...
Cat. No.: HY-L949
1279 compounds

Spirocyclic compounds, with rigid 3D structures, high Fsp³ and strong conformational restriction, are highly privileged scaffolds in small-molecule drug screening. They overcome drawbacks of planar aromatic compounds such as poor solubility, high off-target risks and weak druggability. Their orthogonal bicyclic geometry fits well into protein pockets, improving target affinity, subtype selectivity, metabolic stability and membrane permeability, making them ideal for hit identification against kinases, GPCRs, PPIs and other targets.

Spirocyclic scaffolds have been widely applied in oncology, antivirals, hypertension and CNS diseases, leading to many approved drugs and clinical candidates. SAR studies show that spiro-atom chirality, ring size and heteroatom substitution dominate bioactivity and selectivity, with the scaffold mainly serving as a conformational anchor. Azaspirocycles, spirooxindoles and spirosteranes target GPCRs, kinases, MDM2-p53 and PPIs. Approved drugs including irbesartan, spironolactone and rolapitant confirm their druggability, while revumenib and SAR405838 show promise against undruggable targets.

The MCE Spirocyclic Druglike Library contains over 1,000 diverse, stereospecific molecules selected by Lipinski’s rules. It covers privileged cores such as azaspirocycles, oxaspirocycles and spirooxindoles. These molecules bear rich chiral centers and distinct 3D orientations, reducing non-specific binding and enhancing screening efficiency. Featuring novel scaffolds, the library offers a highly innovative starting point for drug discovery.

Cat. No.: HY-122351AR
CAS No.: 714229-20-6
Research Areas:  

Others

Advantame (Standard) is the analytical standard of Advantame. This product is intended for research and analytical applications. Advantame is an N-substituted derivative of aspartame. Advantame is a high-intensity, low calorie sweetener. Advantame can interact with plasma protein. Advantame has the potential to produce hypotension and inhibit hERG K + channel to produce carditoxicity. Advantame binds to T1R2/T1R3 taste GPCR to form an oligomeric functional selectivity of biased heteromers with NMBR to induce a significant sialidase activity in vitro. Advantame has maternal toxicity (gastrointestinal disturbances) in the prenatal developmental toxicity study in rabbits .
loading...
    loading...
Cat. No.: HY-13771R
CAS No.: 128-13-2
Synonyms: Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .
loading...
    loading...
Cat. No.: HY-10499R
CAS No.: 892546-37-1
Synonyms: BIM-46187 (Standard)
PH-064 (Standard) is the analytical standard of PH-064 (HY-10499). This product is intended for research and analytical applications. PH-064 (BIM-46187) is an orally active inhibitor of the heterotrimeric G-protein complex. PH-064 inhibits SERT activity and attenuates shear stress-induced Akt phosphorylation. PH-064 has potent anti-hyperalgesia activity. PH-064 inhibits G protein-coupled receptor-dependent tumorigenesis. PH-064 can be used in the study of pain (e.g., inflammatory pain, neuropathic pain), GPCR-dependent tumors, and inflammatory lung injury .
loading...
    loading...
Cat. No.: HY-153830
CAS No.: 4201-62-1
Synonyms: C16 Lactosylceramide (d18:1/16:0)
LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0)) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). The levels of LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. In a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder), the expression of LacCer (d18:1/16:0) is also upregulated. LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .
loading...
    loading...
Cat. No.: HY-180583
CAS No.: 3061801-11-1
GRK5-IN-5 (Compound 4a) is a selective G protein-coupled receptor (GPCR) kinase 5 (GRK5) inhibitor with an IC50 of 0.03 μM. GRK5-IN-5 shows IC50 values of 2.2 and 0.036 μM for GRK2 and GRK6. GRK5-IN-5 has potent anti-myocardial hypertrophy activity and also inhibits the proliferation of non-myocardial cells. GRK5-IN-5 can inhibit the abnormal upregulation of hypertrophy marker genes Nppa and Nppb, thus blocking pathological myocardial remodeling. GRK5-IN-5 can be used for the research of cardiac hypertrophy .
loading...
    loading...
Cat. No.: HY-W010516R
CAS No.: 97-61-0
Synonyms: 2-Methylpentanoic acid (Standard)
2-Methylvaleric acid (Standard) is the analytical standard of 2-Methylvaleric acid. This product is intended for research and analytical applications. 2-Methylvaleric acid is a branched short-chain fatty acid (SCFA) produced by the metabolism of branched-chain amino acids by gut microbes. 2-Methylvaleric acid can be used as a potential biomarker for metabolic diseases such as type 2 diabetes, and its content is significantly reduced in the feces of diabetic mice. 2-Methylvaleric acid may regulate host energy metabolism and inflammatory response through G protein-coupled receptors (GPCRs) or histone deacetylase (HDAC) inhibition. 2-Methylvaleric acid can be used to study gut microbe-host interactions and metabolic diseases as a fecal biomarker[1][2].
loading...
    loading...